Redwood City, CACIK 19102644 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
13 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Zenas Biopharma Inc | 5.04M | $182.92M | 25.9% | +126.3K | Added |
| 2 | Arcellx Inc | 2.35M | $153.00M | 21.7% | 0 | Held |
| 3 | Crispr Therapeutics AG | 2.04M | $106.91M | 15.1% | 0 | Held |
| 4 | Design Therapeutics Inc |
| 6.53M |
| $61.22M |
| 8.7% |
| 0 |
| Held |
| 5 | Mineralys Therapeutics Inc | 1.56M | $56.76M | 8.0% | −550.0K | Reduced |
| 6 | Ars Pharmaceuticals Inc | 4.01M | $46.75M | 6.6% | 0 | Held |
| 7 | Oric Pharmaceuticals Inc | 4.51M | $37.75M | 5.3% | 0 | Held |
| 8 | Alumis Inc | 1.96M | $19.13M | 2.7% | 0 | Held |
| 9 | Oruka Therapeutics Inc | 430.3K | $13.04M | 1.8% | 0 | Held |
| 10 | Oculis Holding AG | 641.0K | $12.80M | 1.8% | +318.5K | Added |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio